TEGRETOL CHEWTABS 100 MG TABLET (CHEWABLE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CARBAMAZEPINE

Pieejams no:

NOVARTIS PHARMACEUTICALS CANADA INC

ATĶ kods:

N03AF01

SNN (starptautisko nepatentēto nosaukumu):

CARBAMAZEPINE

Deva:

100MG

Zāļu forma:

TABLET (CHEWABLE)

Kompozīcija:

CARBAMAZEPINE 100MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

MISCELLANEOUS ANTICONVULSANTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108674003; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2017-09-27

Produkta apraksts

_ _
_ _
_Page 1 of 46_
PRODUCT MONOGRAPH
PR
TEGRETOL
®
(carbamazepine)
Pr
TEGRETOL
®
Tablets, 200 mg
Novartis Standard
Pr
TEGRETOL
®
Chewtabs (Chewable Tablets), 100 mg and 200 mg
Novartis Standard
Pr
TEGRETOL
®
CR (Controlled-Release Tablets), 200 mg and 400 mg
Novartis Standard
Pr
TEGRETOL
®
Suspension, 100 mg/tsp (5 mL)
Novartis Standard
Anticonvulsant
For Symptomatic Relief of Trigeminal Neuralgia
Antimanic
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.,
Dorval, Quebec
H9S 1A9
Date of Preparation:
April 26, 1976
Date of Revision:
May 4, 2018
Submission Control No: 213356
TEGRETOL
is a registered trademark.
_ _
_ _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................16
DRUG INTERACTIONS
..................................................................................................20
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...................................